Pathology and molecular updates in tumors of the prostate: towards a personalized approach

Silvia Gasparrini, Alessia Cimadamore, Roberta Mazzucchelli, Marina Scarpelli, Francesco Massari, Maria Rosaria Raspollini, Andrea B. Galosi, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi

Research output: Contribution to journalReview article

3 Scopus citations


Introduction: Treatment planning in patients with prostate neoplasms and prostate cancer (PCa) is generally based on the clinical and pathological molecular markers obtained from prostate needle biopsy and/or radical prostatectomy specimens. Area covered: Pathology of prostate neoplasms is evolving rapidly. Emerging trends include new additions to the 2016 World Health Organization (WHO) tumor classification as well as expanded diagnostic utility of biomarkers and molecular testing in tissue specimens, liquid biopsies and urinary samples, with the following purposes: diagnosis, prognosis and prediction. Expert commentary: The new additions to the 2016 WHO tumor classification, which include pathological definition of Intraductal carcinoma of the prostate (IDC-P) and of a new grading system for PCa, as well as identification of molecular markers, such as TMPRSS2-ERG and AR-V7, may pave the way to personalized therapy for patients with prostate tumors.

Original languageEnglish (US)
Pages (from-to)781-789
Number of pages9
JournalExpert Review of Molecular Diagnostics
Issue number8
StatePublished - Aug 3 2017



  • AR-V7
  • Gleason grading
  • intraductal carcinoma of the prostate
  • liquid biopsies
  • prognostic grade grouping
  • Prostate cancer
  • urinary biomarkers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Gasparrini, S., Cimadamore, A., Mazzucchelli, R., Scarpelli, M., Massari, F., Raspollini, M. R., Galosi, A. B., Lopez-Beltran, A., Cheng, L., & Montironi, R. (2017). Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Review of Molecular Diagnostics, 17(8), 781-789.